Last reviewed · How we verify
ACH-0144471
ACH-0144471 is a monoclonal antibody targeting the CD40 receptor.
ACH-0144471 is a monoclonal antibody targeting the CD40 receptor. Used for Systemic lupus erythematosus.
At a glance
| Generic name | ACH-0144471 |
|---|---|
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Drug class | Monoclonal antibody |
| Target | CD40 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
CD40 is a costimulatory molecule that plays a key role in the activation of immune cells. By targeting CD40, ACH-0144471 aims to modulate the immune response and potentially treat various autoimmune and inflammatory conditions.
Approved indications
- Systemic lupus erythematosus
Common side effects
- Infusion-related reactions
- Headache
- Fatigue
Key clinical trials
- A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH (PHASE3)
- Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab (PHASE2)
- A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 (PHASE2)
- A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) (PHASE2)
- A Study of the Effects of Food and Age on Danicopan (PHASE1)
- A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) (PHASE2)
- Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) (PHASE2)
- Study of the Metabolism of Danicopan in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |